Adenocarcinoma, Clear Cell - 82 Studies Found
Completed |
: Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer :
|
Active, not recruiting |
: Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer :
|
Active, not recruiting |
: Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer :
|
Completed |
: Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer :
|
Recruiting |
: Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer :
: |
Active, not recruiting |
: Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer :
|
Recruiting |
: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers :
|
Recruiting |
: Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer :
|
Recruiting |
: A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors :
: Drug: PT2977 PT2977 is a highly selective small molecule that inhibits the function of the HIF-2α t |
Active, not recruiting |
: Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer :
|